Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUPERVAC-9
- Development stage
- Unknown
- Lead developer
- Vetal Company
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
SUPERVAC-9 is an inactivated polyvalent combined vaccine developed by Vetal Company for the prevention of clostridial diseases and related bacterial infections in livestock, including sheep, goats, and cattle. The vaccine contains antigens from nine distinct bacterial valents: *Corynebacterium pseudotuberculosis*, *Salmonella typhimurium*, *Clostridium perfringens* (types B, C, and D), *Clostridium novyi* type A, *Clostridium septicum*, *Clostridium chauvoei*, and *Clostridium tetani*. It is formulated with an aluminum hydroxide gel adjuvant to enhance the immune response. The vaccine induces active immunity against conditions such as enterotoxemia, blackleg, malignant edema, tetanus, salmonellosis, and caseous lymphadenitis (pseudotuberculosis).
- Brand names
- SUPERVAC-9SUPERVAC9SUPERVAC 9
- Other names
- Combined Clostridial Vaccine
02
Targets
TT (Clostridium tetani antigens/toxoids)Corynebacterium pseudotuberculosis antigensClostridium novyi type A antigens/toxoidsATX (Clostridium septicum alpha-toxin)Clostridium perfringens type D antigens/toxoidsClostridium perfringens type B antigens/toxoids
Beyond the preview
Go deeper on SUPERVAC-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUPERVAC-9.